Financial News

Geron Begins Embryonic Stem Cell Treatment In Humans

Geron Corp. (Nasdaq: GERN) began the nation's first clinical trial using embryonic stem cells for the treatment of injuries in humans lifting the stock price 70 cents to close at $6.37.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info